fda warning letters compounded semaglutide tirzepatide september 2025 Drug Recalls and Warnings: Recalls for and Tirzepatide, Wegovy; Facility Beyond the Headlines: FDA Warning

Initial results from a randomized controlled trial indicated that it reduced weight and improved diabetic control

Tell your doctor about all the medications you are taking, including prescription drugs, over-the-counter medications, and supplements

4.75 out of 5 4.79 out of 5

All doses of orforglipron in the ATTAIN-2 trial demonstrated a dose-dependent reduction in body weight and HbA1c at 72 weeks, Nasreen Alfaris , MD, MPH, consultant at the Obesity, Endocrine and Metabolism Center at King Fahad Medical City in Riyadh, Saudi Arabia, said during a presentation

Monitor IGF-1 levels every 812 weeks to confirm sermorelin efficacy